Will Novavax, Inc. (NASDAQ:NVAX) be Surging after Earnings Report?

Novavax, Inc. (NASDAQ:NVAX) moved down -3.18% and closed its last trading session at $1.52. This Medical Sector stock currently has the Market Capitalization of 425.8 Million. The Average Volume for the stock is measured as 17.21 Million. The Stock has a 52-Week High of $9.23 and 52-Week Low of $1.16 following the dates, it touched its 52-Week High on Dec 2, 2015 and 52-Week Low on Sep 16, 2016. Currently, the Return on Assets value for the trailing twelve months is -56.3% with the Return on Equity and Return on Investment of -112.4% and -53.6% respectively. This firm currently has YTD (year to date) performance of -81.88 Percent which is not good. The Short Ratio for the stock is 4.43.

Novavax, Inc. (NASDAQ:NVAX) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.99. The TTM operating margin is 0 percent.

Novavax, Inc. (NASDAQ:NVAX) is due to report its Earnings on Wed 9 Nov (In 17 Days). The estimated EPS for the current quarter is said to be $-0.27. Following Earnings result, share price were DOWN 18 times out of last 27 Qtrs. The stock has reduced about -79.9% since it reported its last earnings. The Closing price of Novavax, Inc. (NASDAQ:NVAX) at Last Earnings was $7.57 as compared to the previous closing price of $1.57. The Predicted Move on the 7th day after Novavax, Inc. (NASDAQ:NVAX) will release its earnings at about 6%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Novavax, Inc. (NASDAQ:NVAX) beats earnings by 16%, The Stock Missed Earnings  7  times and has met earnings  3  times.

Earnings History:

We will discuss the past Quarters Earnings below:

Novavax, Inc. (NASDAQ:NVAX) reported its previous quarter on 08/09/2016 where it reported the Actual Earnings of $-0.29. The Closing price before the company posted its earnings was $7.57. The Stock declined on the very next day of earnings and maintained its stock price at $6.83 by showing a % change of -9.78 percent from its previous closing price. The Next Day Volume after Earnings was reported as 11.1 Million. On the 7th day After Earnings Report, the stock hit its share price as $7.38 by showing -2.51% decrease from the Stock price Before Earnings were reported.

On 05/04/2016, the stock reported the EPS of $-0.29 where Analysts were projecting the EPS to be $-0.27 showing a difference of $-0.02. Thus Surprise Factor was there with -7.4 percent. Before Earnings Announcement on 05/04/2016, the firm had its stock price of $4.78. And immediately on the next day after earnings announcement, the stock declined -4.18% and closed its trading session at $4.58. On 7th Day after earnings release, Novavax, Inc. (NASDAQ:NVAX) dropped to -6.69% from $4.78 to $4.46.

On 02/29/2016, Analysts were suspecting EPS of $-0.14/share where Novavax, Inc. (NASDAQ:NVAX) reported its Actual EPS of $-0.29. Thus showing a Surprise of -107.1 percent. The Closing Price of the stock before earnings was $4.71 while on the Next day the stock closed its trading session at $4.36 with a percentage change of -7.43% from the price of 4.71 before Earnings. The Stock Closing Price on the 7th day of earnings was $4.86.

Company Profile:

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.